Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-06-02 00:00:00 ET · period of report 2024-08-10 · accession 0002001011-25-000037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-02 | 2025-05-15 | LGND | Reardon Andrew | CLO, Sec | S - Sale | $104.00 | -1,000 | 32.9K | -3% | -$104.0K | |
| 2025-06-02 | 2024-08-10 | LGND | Reardon Andrew | CLO, Sec | F - Tax | $100.16 | -897 | 21.6K | -4% | -$89.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-15 | S | D | 1,000 | $104.00 | 32,903 | D | — | — | (F2) The total includes 17 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-08-10 | F | D | 897 | $100.16 | 21,637 | D | — | — |